Pharmacological tools selectively targeting the LSD1-SOX2 axis might be appropriate to experimentally uncouple the apparently counterintuitive capacity of LSD1 blockade to promote reprogramming phenomena by regulating the balance between pluripotency and differentiation [78–83] while preventing SOX2-driven cancer stemness. This evidence concerns the gene KDM1A and cancer.